Clinical profile of donepezil in the treatment of Alzheimer's disease

Gerontology

Volumn 45, Issue SUPPL. 1, 1999, Pages 23-32

  Doody, Rachelle S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Donepezil

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MALE; MUSCLE CRAMP; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0032928788     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052761     Document Type: Conference Paper

References (62)

1. Evans D: Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990; 68:267-289.
2. Yankner BA, Mesulam M-M: Seminars in medicine of the Beth Israel Hospital, Boston. β-Amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med 1991;325:1849-1857.
3. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO: Prevalence of Alzheimer's disease in a community population of older persons. JAMA 1989;262:2551-2556.
4. Barclay LL, Zemcov A, Blass JP, Sansone J: Survival in Alzheimer's disease and vascular dementias. Neurology 1985;35:834-840.
5. Knopman DS, Kitto J, Deinard S, Heiring J: Longitudinal study of death and institutionalization in patients with primary degenerative dementia. J Am Geriatr Soc 1988;36:108-112.
6. Lanska DJ: Dementia mortality in the United States. Results of the 1986 National Mortality Followback Study. Neurology 1998;50:362-367.
7. Geula C, Mesulam M-M: Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease: in Terry RD, Katzman R, Bick KL (eds): Alzheimer Disease. New York, Raven Press, 1994, pp 263-291.
8. Wenk GL: The nucleus basalis magnocellularis cholinergic system: One hundred years of progress. Neurobiol Learn Mem 1997;67:85-95.
9. Appleyard ME: Secreted acetylcholinesterase: Non-classical aspects of a classical enzyme. Trends Neurosci 1992;15:485-490.
10. Geula C, Mesulam MM: Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 1995;9(suppl 2):23-28.
11. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258:304-307.
12. Francis PT, Cross AJ, Bowen DM: Neurotransmitters and neuropeptides; in Terry RD, Katzman R, Pick KL (eds): Alzheimer Disease. New York, Raven Press, 1994, pp 247-261.
13. Quirion R, Richard J, Wilson A: Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats. Synapse 1994;17: 92-100.
14. Winkler J, Suhr ST, Gage FH, Thal LJ, Fisher LJ: Essential role of neocortical acetylcholine in spatial memory. Nature 1995;375:484-487.
15. Thal LJ, FuId PA, Masur DM, Sharpless NS: Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 1983;13:491-496.
16. Mohs RC, Davis BM, Johns CA, Mathe AA, Greenwald BS, Horvath TB, Davis KL: Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142: 28-33.
17. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, for the Tacrine Study Group: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271: 985-991.
18. Smucker WD: Maximizing function in Alzheimer's disease: What role for tacrine? Am Fam Physician 1996;54:645-652.
19. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S: Long-term tacrine (Cognex™) treatment: Effects on nursing home placement and mortality. Neurology 1996;47:166-177.
20. Cummings JL, Kaufer DL: Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996;47:876-883.
21. Gorman DG, Read S, Cummings JL: Cholinergic therapy of behavioural disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-234.
22. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM: Effects of xanolmeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
23. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB: Effect of tacrine on language, praxis, and noncognitive behavioural problems in Alzheimer's disease. Arch Neurol 1997;54:836-840.
24. Cardozo MG, Iimura Y, Sugimolo H, Yamanishi Y, Hopfinger AJ: QSAR analysis of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35:584-589.
25. Cardozo MG, Kawai T, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ: Conformational analysis and molecular-shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992;35: 590-601.
26. 14C). J Label Compounds Radiopharm 1989;27:835-839.
27. Inoue A, Kawai T, Wakita M, Iimura Y, Sugimoto H, Kawakami Y: The stimulated binding of (±)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- 1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses. J Med Chem 1996;39:4460-4470.
28. Kawakami Y, Inoue A, Kawai T, Wakita M, Sugimoto H, Hopfinger AJ: The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem 1996;4:1429-1556.
29. Pang YP, Kozikowski AP: Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYS-DOC program. J Comput Aided Mol Des 1994; 8:683-693.
30. Sugimoto H, Tsuchiya Y, Sugumi H, Higurashi K, Karibe N, Iimura Y, Sasaki A, Kawakami Y, Nakamura T, Araki S, Yamanishi Y, Yamatsu K: Novel piperidine derivatives. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives. J Med Chem 1990;33:1880-1887.
31. Sugimoto H, Tsuchiya Y, Sugumi H, Higurashi K, Karibe N, Iimura Y, Sasaki A, Araki S, Yamanishi Y, Yamatsu K: Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-(2-phthalimidoethyl)piperidine and related derivatives. J Med Chem 1992;35:4542-4548.
32. Tong W, Collantes ER, Chen Y, Welsh WJ: A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinestcrase inhibitors. J Med Chem 1996;39:380-387.
33. Rogers SL, Yamanishi Y, Yamatsu K: E2020: The pharmacology of a piperidine cholinesterase inhibitor, in Becker R, Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston, Birkhäuser, 1991, pp 314-320.
34. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K: Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethyoxy-1-indanon)-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett 1992;2:871-876.
35. Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepczil HCl following single oral doses. Br J Clin Pharmacol 1998;46(suppl 1):1-6.
36. Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998;46(suppl 1):7-12.
37. Rogers SL, Farlow MR, Doody RS, Mohs RC, Friedhoff LT and The Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
38. Rogers SL, Doody RS, Mohs RC, Friedhoff LT and The Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158:1021-1031.
39. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
40. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder, ed 3 rev. Washington, APA, 1987.
41. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State'. A practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975;12:189-198.
42. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
43. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
44. Schneider L, Olin J, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH and the Alzheimer's Disease Cooperative Study: Validity and Reliability of the Alzheimer's Disease Cooperative Study Unit Clinical Global Impression of Change (ADCSU-CGIC). Alzheimer Dis Assoc Disord 1997;11:522-532.
45. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G: Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992;31:242-249.
46. Friedhoff LT, Rogers SL: Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease - Results of a preliminary evaluation. Neurology 1997;48:A100(P02.026).
47. Becker RE, Colliver J, Elble R, Feldman E, Giacobini E, Kumar V, Markwell S, Moriearty P, Parks R, Shillcutt SD, Unni L, Vicari S, Womack C, Zee RF: Effects of metrifonate, a long acting cholinesterase inhibitor in Alzheimer's disease: Report of an open trial. Drug Dev Res 1990;19:425-434.
48. Rogers SL, Friedhoff LT: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
49. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8:67-75.
50. ARICEPT® (donepezil hydrochloride tablets). US Package Insert, January 9, 1998.
51. Tiseo PJ, Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998;46(suppl 1):13-18.
52. 14C-donepezil in healthy volunteers: A single-dose study. Br J Clin Pharmacol 1998;46(suppl 1):19-24.
53. Tiseo PJ, Foley K, Friedhoff LT: An evaluation of the pharmacokinetics of donepezii HCl in patients with moderately-to severely-impaired renal function. Br J Clin Pharmacol 1998; 46(suppl 1}:56-60.
54. Tiseo PJ, Vargas R, Perdomo CA. Friedhoff LT: An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol 1998;46(suppl 1):51-55.
55. Tiseo PJ, Perdomo CA, Friedhoff LT: Concurrent administration of donepezil HCl and digoxin: Assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998;46(suppl 1):40-44.
56. Tiseo PJ, Perdomo CA, Friedhoff LT: Concurrent administration of donepezil HCl and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(suppl 1):25-29.
57. Tiseo PJ, Perdomo CA, Friedhoff LT: Concurrent administration of donepezil HCl and ketoconazole: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(suppl l):30-34.
58. Tiseo PJ, Rogers SL, Perdomo CA, Friedhoff LT: The effect of cimelidine and ketoconazole on the pharmacokinetics of donepezil HCl. Clin Pharmacol Ther 1998;63:234.
59. Tiseo PJ, Foley K, Friedhoff LT: The effect of multiple doses of donepezil HCI on the phar-macokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46(suppl 1):45-50.
60. Tiseo PJ, Foley K, Friedhoff LT: Concurrent administration of donepezil HCl and theophylline: Assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998; 46(suppl 1):35-39.
61. Kaufer DI, Catt K, Pollock BG, Lopez OM, DeKosky ST: Donepezil in Alzheimer's disease: Relative cognitive and neuropsychiatric responses and impact on caregiver distress. Neurology 1998;50(suppl 4):A89(P02.013).
62. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.